Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment
Research output: Contribution to journal › Review › Research › peer-review
PURPOSE OF REVIEW: To review the latest advances in migraine management with a focus on medications specifically developed for the treatment of migraine.
RECENT FINDINGS: Randomized clinical trials demonstrated the efficacy of calcitonin gene-related peptide (CGRP) mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist gepants for acute abortion and prevention of migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is another signaling molecule of interest and represents a potential new drug class of mechanism-based migraine medications. Drugs targeting PACAP are currently undergoing clinical trials, and the coming years will reveal whether this class of drugs will expand our therapeutic armamentarium.
SUMMARY: Here, we summarize the role of CGRP and PACAP in migraine pathophysiology and discuss novel therapies targeting the CGRP and PACAP signaling pathways.
| Original language | English |
|---|---|
| Journal | Current Opinion in Endocrinology, Diabetes and Obesity |
| Volume | 29 |
| Issue number | 2 |
| Pages (from-to) | 225-231 |
| Number of pages | 7 |
| ISSN | 1752-296X |
| DOIs | |
| Publication status | Published - 1 Apr 2022 |
Bibliographical note
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ID: 73907615